Effect of Exogenous Growth Hormone on Ocular Findings

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

90 participants

Study Classification

OBSERVATIONAL

Study Start Date

2022-03-20

Study Completion Date

2023-10-22

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Body size and eye function play an essential role in adapting to the environment and human survival. Growth hormone is commonly recognized by its effect on the height of individuals; Although from an evolutionary perspective, the effects of growth hormone on eye development are more important. Although the effect of growth hormone on eye development has not been accurately determined, the results of a number of studies suggest the effect of growth hormone on eye development.

Despite the large number of studies that have investigated the effects of growth hormone on height growth, there are few studies that have investigated the effects of growth hormone on the eye.

To the best of our knowledge, no study has been conducted to investigate the effect of growth hormone on ocular findings of patients with early or precocious puberty. Therefore, we intend to investigate the effect of growth hormone on ocular findings of patients with early or precocious puberty.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Retrospective Study Of The Influence Of Age At Start Of Growth Hormone Treatment On Height Gain In Children Born Small for Gestational Age

NCT01897753

Small For Gestational Age (SGA)

COMPLETED

GH and Cardiovascular Risk Factors

NCT01877512

Growth Hormone Deficiency Cardiovascular Diseases Metabolic Syndrome +2 more

COMPLETED PHASE4

Endocrine Dysfunction and Growth Hormone Deficiency in Children With Optic Nerve Hypoplasia

NCT00140413

Growth Hormone Deficiency Septo-Optic Dysplasia Hypopituitarism

COMPLETED PHASE4

Impact of Screens on Children's Growth

NCT07026812

Growth Disorders

COMPLETED

rhGH Therapy on Hepatic Drug Metabolism

NCT00458991

Growth Hormone Deficiency, Dwarfism

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Investigators will achieve the following data from the participants:

1. Demographics
2. Past medical history

3\. Bone and calendar age

4- Stage of puberty

5- Ocular examination

6\. Ocular biometry

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Precocious Puberty Early Puberty Refraction Error

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Early or precocious puberty who receive GH

Children with early or precocious puberty who receive exogenous growth hormone

No interventions assigned to this group

Early or precocious puberty who does not receive GH

Children with early or precocious puberty who does not receive exogenous growth hormone

No interventions assigned to this group

Healthy

Healthy children without any past medical history

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

Sample group (with early or precocious puberty):

1. Children with precocious puberty based on Tanner classification
2. Girls 4 to 10 years old
3. Boys aged 4 to 11
4. No known eye problems including: history of eye trauma, eye surgery 5- lack of family history of glaucoma or increased intraocular pressure

6\. Lack of previous history of receiving growth hormone 7. Lack of systemic disease or known syndromes 8. Consent to participate in the study

Exclusion Criteria

1. Incidence of growth hormone adverse reactions leading to discontinuation of treatment
2. Changing the patient's treatment plan during the study
3. Ocular complications requiring treatment during the study
4. Unwillingness of the patient to continue participating in the study

Minimum Eligible Age

4 Years

Maximum Eligible Age

11 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes